Receptor Activator of Nuclear Factor-kappa B
"Receptor Activator of Nuclear Factor-kappa B" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A tumor necrosis factor receptor family member that is specific for RANK LIGAND and plays a role in bone homeostasis by regulating osteoclastogenesis. It is also expressed on DENDRITIC CELLS where it plays a role in regulating dendritic cell survival. Signaling by the activated receptor occurs through its association with TNF RECEPTOR-ASSOCIATED FACTORS.
| Descriptor ID |
D053246
|
| MeSH Number(s) |
D12.776.543.750.705.852.760.345
|
| Concept/Terms |
Receptor Activator of Nuclear Factor-kappa B- Receptor Activator of Nuclear Factor-kappa B
- Receptor Activator of Nuclear Factor kappa B
- Receptor Activator of NF-kappa B
- Receptor Activator of NF kappa B
- TRANCE-R
- TRANCE R
- TRANCE Receptor
- RANK Protein
- Receptor Activator of NF-kappaB
- Receptor Activator of NF kappaB
- NF-KappaB Receptor Activator
- Activator, NF-KappaB Receptor
- NF KappaB Receptor Activator
- Receptor Activator, NF-KappaB
- Receptors, Tumor Necrosis Factor, Member 11a
- Receptor Activator of Nuclear Factor-kappaB
- Receptor Activator of Nuclear Factor kappaB
- Tumor Necrosis Factor Receptor Superfamily, Member 11a
- NF-Kappa B Receptor Activator
- NF Kappa B Receptor Activator
- CD265 Antigen
- Antigen, CD265
- TNFRSF11A Protein
|
Below are MeSH descriptors whose meaning is more general than "Receptor Activator of Nuclear Factor-kappa B".
Below are MeSH descriptors whose meaning is more specific than "Receptor Activator of Nuclear Factor-kappa B".
This graph shows the total number of publications written about "Receptor Activator of Nuclear Factor-kappa B" by people in this website by year, and whether "Receptor Activator of Nuclear Factor-kappa B" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1999 | 0 | 1 | 1 |
| 2001 | 0 | 1 | 1 |
| 2002 | 0 | 1 | 1 |
| 2003 | 0 | 3 | 3 |
| 2004 | 0 | 4 | 4 |
| 2005 | 0 | 4 | 4 |
| 2006 | 0 | 4 | 4 |
| 2007 | 1 | 0 | 1 |
| 2008 | 1 | 0 | 1 |
| 2013 | 1 | 0 | 1 |
| 2015 | 1 | 1 | 2 |
| 2016 | 0 | 1 | 1 |
| 2017 | 1 | 0 | 1 |
| 2022 | 0 | 1 | 1 |
| 2023 | 0 | 1 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Receptor Activator of Nuclear Factor-kappa B" by people in Profiles.
-
Early identification of a 12-bp tandem duplication in TNFRSF11A encoding receptor activator of nuclear factor-kappa B (RANK): Clinical characterization and response to bisphosphonate therapy. Bone. 2023 05; 170:116698.
-
Histopathologic and transcriptomic phenotypes of a conditional RANKL transgenic mouse thymus. Cytokine. 2022 12; 160:156022.
-
Porphyrin Derivatives Inhibit the Interaction between Receptor Activator of NF-?B and Its Ligand. ChemMedChem. 2017 10 20; 12(20):1697-1702.
-
Poor prognosis of patients with triple-negative breast cancer can be stratified by RANK and RANKL dual expression. Breast Cancer Res Treat. 2017 Jul; 164(1):57-67.
-
Loss of glutaredoxin 3 impedes mammary lobuloalveolar development during pregnancy and lactation. Am J Physiol Endocrinol Metab. 2017 03 01; 312(3):E136-E149.
-
Distribution of alkaline phosphatase, osteopontin, RANK ligand and osteoprotegerin in calcified human carotid atheroma. Protein J. 2015 Oct; 34(5):315-28.
-
Aberrant Activation of the RANK Signaling Receptor Induces Murine Salivary Gland Tumors. PLoS One. 2015; 10(6):e0128467.
-
Bone marrow stromal cells derived MCP-1 reverses the inhibitory effects of multiple myeloma cells on osteoclastogenesis by upregulating the RANK expression. PLoS One. 2013; 8(12):e82453.
-
Deubiquitinating enzyme CYLD negatively regulates RANK signaling and osteoclastogenesis in mice. J Clin Invest. 2008 May; 118(5):1858-66.
-
TRAFs in RANK signaling. Adv Exp Med Biol. 2007; 597:152-9.